Health Discovery Labs has been developing a revolutionary Electrical Muscle Stimulation (EMS) system called MyokinE, which provides a non-volitional exercise strategy (i.e., a muscle stimulation therapy that can be administered to unconscious patients) primarily intended for use with critically-ill patients who are at risk of developing ICUAW. On average, the MyokinE system will reduce the length of stay in the ICU by 1.6 days for mechanically ventilated patients.
Up to 80% of patients admitted to Intensive Care Units (ICUs) develop some form of neuromuscular dysfunction, which often leads to a much more serious complication known as ICU Acquired Weakness (ICUAW). ICUAW is a global muscle weakness that can develop in as little as a few hours after admission to the ICU and results in prolonged hospital stays (both in the ICU and afterwards in the ward), increased healthcare costs and reductions in health-related quality of life and expectancy.